SCHEMBL16632663

SCHEMBL16632663

CCc1nc2cc(N(C)Cc3ccc(OC)cc3)ncc2cc1-c1ccc(F)c(N)c1

nearest known ligand 0.40

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 2/20 0.40
PKM P14618 2/20 0.36
SMN1; SMN2 Q16637 2/20 0.36
HSD17B10 Q99714 2/20 0.36
NPC1 O15118 1/20 0.36
TP53 P04637 1/20 0.36
RAB9A P51151 1/20 0.36
ADORA2A P29274 1/20 0.35
DHFR P00374 1/20 0.34
RPS6KB1 P23443 1/20 0.33
HEXA P06865 1/20 0.33
HEXB P07686 1/20 0.33
EGFR P00533 1/20 0.33
CSF1R P07333 1/20 0.33
USP7 Q93009 1/20 0.33
GRM5 P41594 1/20 0.33
LMNA P02545 1/20 0.32
NOS1 P29475 1/20 0.32
FGFR1 P11362 1/20 0.32
HDAC3 O15379 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL15272719 0.89 ALDH1A1 (0.43) ALDH1A1PKMSMN1; SMN2HSD17B10NPC1
SCHEMBL15289531 0.88 ALDH1A1 (0.39) ALDH1A1PKMSMN1; SMN2ADORA2ADHFR
SCHEMBL15289527 0.87 ALDH1A1 (0.37) ALDH1A1PKMSMN1; SMN2ADORA2ADHFR
SCHEMBL16632183 0.85 KDR (0.39) ALDH1A1SMN1; SMN2NPC1TP53RAB9A
SCHEMBL30236674 0.84 ALDH1A1 (0.43) ALDH1A1PKMSMN1; SMN2HSD17B10NPC1
SCHEMBL15289544 0.80 KDR (0.36) SMN1; SMN2NPC1RAB9AFGFR1HDAC3
SCHEMBL15289560 0.79 BRAF (0.53) LMNAFGFR1
SCHEMBL29699175 0.79 ALDH1A1 (0.42) ALDH1A1PKMSMN1; SMN2ADORA2ADHFR
SCHEMBL15289526 0.79 ALDH1A1 (0.42) ALDH1A1PKMSMN1; SMN2ADORA2ADHFR
SCHEMBL15289530 0.78 ALDH1A1 (0.41) ALDH1A1ADORA2ADHFRHDAC3HDAC1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9187474-B2 Raf inhibitor compounds DECIPHERA PHARMACEUTICALS, LLC (US) 2015-11-17 US disclosed
US-9187474-B2 Raf inhibitor compounds DECIPHERA PHARMACEUTICALS, LLC (US) 2015-11-17 US disclosed
US-9187474-B2 Raf inhibitor compounds DECIPHERA PHARMACEUTICALS, LLC (US) 2015-11-17 US disclosed
US-20150105367-A1 RAF INHIBITOR COMPOUNDS DECIPHERA PHARMACEUTICALS, LLC 2015-04-16 US disclosed
US-20150105367-A1 RAF INHIBITOR COMPOUNDS DECIPHERA PHARMACEUTICALS, LLC 2015-04-16 US disclosed
US-20150105367-A1 RAF INHIBITOR COMPOUNDS DECIPHERA PHARMACEUTICALS, LLC 2015-04-16 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20150105367-A1 RAF INHIBITOR COMPOUNDS BRAF, RAF1, NRAS ALDH1A1 1426/4885PKM 1983/4885SMN1; SMN2 3679/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.